Symbols

Why Did Calidi Biotherapeutics Stock Plunge 10.55%?

Generated by AI AgentAinvest Pre-Market Radar

Monday, Jul 28, 2025 6:47 am ET1min read

Aime Summary

- Calidi Biotherapeutics' stock fell 10.55% pre-market before announcing a 1-for-12 reverse stock split effective August 5, 2025.

- The split aims to raise per-share price to attract institutional investors and improve liquidity while addressing market concerns.

- Investors monitor the move's impact on holdings and market perception, with analysts viewing it as a proactive step for long-term stability.

On July 28, 2025, Calidi's stock experienced a significant drop of 10.55% in pre-market trading, marking a notable decline in its share price.

Calidi Biotherapeutics has announced a reverse stock split, which is expected to take effect on August 5, 2025. This 1-for-12 split will adjust the trading basis of the company's shares, potentially impacting investor holdings and market perception.

The reverse stock split is a strategic move by CalidiCLDI-- to increase the per-share price, which could attract institutional investors and improve liquidity. This decision reflects the company's efforts to enhance its financial profile and market standing.

Investors and analysts are closely monitoring the impact of this reverse stock split on Calidi's stock performance. The move is seen as a proactive measure to address potential market concerns and stabilize the company's share price in the long term.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue